Product
Platinum-based Systemic Chemotherapy
1 clinical trial
3 indications
Indication
Ovarian CancerIndication
fallopian tube cancerIndication
Peritoneal CancerClinical trial
A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01